1
|
Nævus congénitaux et mélanomes pédiatriques, apports de la génétique. Ann Dermatol Venereol 2020; 147:703-705. [DOI: 10.1016/j.annder.2020.07.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
2
|
Ponomarev IV, Topchy SB, Pushkareva AE, Andrusenko YN, Shakina LD. Treatment of сongenital melanocytic nevus in infants and children by a dual-wavelengths copper vapor laser. VESTNIK DERMATOLOGII I VENEROLOGII 2020. [DOI: 10.25208/vdv1133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
Introduction.Congenital melanocytic nevus (CMN) is detected at birth or shortly after birth in 1% of infants. The localization of CMN in aesthetically significant areas causes a decline in child self-esteem and causes concern for his parents. Surgical excision of skin areas with CMN is associated with an increased risk of cosmetic side effects and is often followed by long-term stress conditions after the invasive intervention.
Aim of the study.To evaluate the efficacy of the CMN removal in infants, children and adolescents with the dual-wavelengths copper vapor laser (CVL) radiation.
Patients and Methods.Medium-sized (up to 9 cm) single CMN was treated in nine fair-skinned patients: seven girls and two boys, aged from 2 months to 16 years. The procedures were carried out at an average CVL power of 0.61.0 W, with a power ratio of 3:2 at 511 nm and 578 nm wavelengths, and an exposure time of 0.20.3 s. Light spot diameter 1 mm. The treatment was carried out during 210 sessions with an interval of 12 months between sessions.
Results.In children and adolescents, the treatment of CMN with CVL dual-wavelengths radiation made it possible to achieve significant clarification of the involved area without hypertrophic scars. The duration of the healing of the irradiated area lasted 23 weeks. Side effects were manifested with subtle skin atrophy.
Conclusion.The high efficacy of CVL removal of medium-sized CMN in infants and children using the dual-wavelengths CVL radiation without pronounced side effects allows introducing such an approach in the clinical practice of pediatric dermatologists and cosmetologists.
Collapse
|
3
|
Chang LW, Iqbal R, Badal B, Bernstein D, Mendelson K, Solovyov A, Friedlander P, Phelps R, Goodheart H, Desman G, Greenbaum BD, Tok Celebi J. Genomic analysis of metastatic melanoma in an adult with giant congenital melanocytic nevus. Pigment Cell Melanoma Res 2020; 33:633-636. [PMID: 32096295 DOI: 10.1111/pcmr.12872] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Li-Wei Chang
- Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Ramiz Iqbal
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Brateil Badal
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Daniel Bernstein
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Karen Mendelson
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alexander Solovyov
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Philip Friedlander
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Robert Phelps
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Herbert Goodheart
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Garrett Desman
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Benjamin D Greenbaum
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Julide Tok Celebi
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|
4
|
Treatment of Congenital Melanocytic Nevi in the Eyelid and Periorbital Region With Ablative Lasers. Ann Plast Surg 2019; 83:S65-S69. [DOI: 10.1097/sap.0000000000002094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Rouillé T, Aractingi S, Kadlub N, Fraitag S, How-Kit A, Daunay A, Hivelin M, Moguelet P, Picard A, Fontaine RH, Guégan S. Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi. J Invest Dermatol 2019; 139:2004-2015.e13. [PMID: 31059696 DOI: 10.1016/j.jid.2019.03.1156] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 03/20/2019] [Accepted: 03/26/2019] [Indexed: 12/15/2022]
Abstract
The management of large congenital melanocytic nevi (lCMN) is based exclusively on iterative surgical procedures in the absence of validated medical therapy. The aim of our study was to develop an intra-lesional medical treatment for lCMN. Seventeen patients harboring NRAS-mutated lCMN were included. Nevocytes obtained from lCMN displayed an overactivation of mitogen-activated protein kinase and phosphoinositide 3-kinase (Akt) pathways. Mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) and Akt inhibitors reduced the nevosphere diameter in sphere-forming assays, as well as cell viability and proliferation in in vitro assays. Standardized lCMN explants were then cultured ex vivo with the same inhibitors, which induced a decrease in MelanA+ and Sox10+ cells in both epidermis and dermis. Finally, intradermal injections of these inhibitors were administered within standardized lCMN xenografts in Rag2-/- mice. They induced a dramatic decrease in nevocytes in treated xenografts, which persisted 30 days after the end of treatment. Using original nevus explant and xenograft preclinical models, we demonstrated that intradermal MEK/Akt inhibition might serve as neoadjuvant therapy for the treatment of NRAS-mutated congenital melanocytic nevi to avoid iterative surgeries.
Collapse
Affiliation(s)
- Thomas Rouillé
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Sorbonne Université, Paris, France
| | - Selim Aractingi
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Université Paris-Descartes, Paris, France; AP-HP, Hôpital Cochin, Department of Dermatology, Paris, France
| | - Natacha Kadlub
- Université Paris-Descartes, Paris, France; AP-HP, Hôpital Necker-Enfants-Malades, Department of Maxillofacial and Plastic Surgery, Paris, France
| | - Sylvie Fraitag
- AP-HP, Hôpital Necker-Enfants-Malades, Department of Pathology, Paris, France
| | - Alexandre How-Kit
- Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France
| | - Antoine Daunay
- Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France
| | - Mikael Hivelin
- Université Paris-Descartes, Paris, France; AP-HP, Hôpital Européen Georges-Pompidou, Department of Plastic Surgery, Paris, France
| | | | - Arnaud Picard
- Université Paris-Descartes, Paris, France; AP-HP, Hôpital Necker-Enfants-Malades, Department of Maxillofacial and Plastic Surgery, Paris, France
| | - Romain H Fontaine
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Sorbonne Université, Paris, France
| | - Sarah Guégan
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Université Paris-Descartes, Paris, France; AP-HP, Hôpital Cochin, Department of Dermatology, Paris, France.
| |
Collapse
|
6
|
Basu D, Salgado CM, Patel JR, Zabec J, Hoehl RM, Bauer B, Reyes-Múgica M. Pluripotency markers are differentially induced by IGF1 and bFGF in cells from patients' lesions of large/giant congenital melanocytic nevi. Biomark Res 2019; 7:2. [PMID: 30675361 PMCID: PMC6332894 DOI: 10.1186/s40364-018-0152-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 12/28/2018] [Indexed: 11/10/2022] Open
Abstract
Factors regulating transcription of pluripotency genes in congenital nevo-melanocytes are not known. Nevo-melanocytes belong somewhere in-between the ends of a spectrum where the normal epidermal melanocyte represents one end and a melanoma cell with multiple genetic abnormalities represents the other. Cells from large/giant congenital nevi (L/GCMN), unlike normal melanocytes, grow colonies on soft agar and express pluripotency markers, similar to melanoma cells. In this study normal melanocytes, SKMEL28 melanoma cells and nevo-melanocytes isolated from three L/GCMN patients were exposed to niche factors bFGF and IGF1 in vitro at physiological doses, and expression of a panel of pluripotency markers was determined by RT-PCR. While normal melanocytes did not show any significant transcriptional change in the genes studied, bFGF induced transcription of Sox2 and Bmi1 in melanoma cells. Patients' cells showed differential expression, with Sox10 being common to C76N and PD1N, while only Sox2 and Bmi1 were upregulated in C139N. IGF1 on the other hand induced unique sets of genes in each individual sample. We conclude that expression of pluripotency genes in L/GCMN cells is affected by niche factors bFGF and IGF1; however, each individual growth factor induced a unique set of genes in a patient's cells.
Collapse
Affiliation(s)
- Dipanjan Basu
- Department of Pathology, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15224 USA
| | - Cláudia M Salgado
- Department of Pathology, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15224 USA
| | - Janki R Patel
- 2Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA USA
| | - Joie Zabec
- 2Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA USA
| | - Ryan M Hoehl
- 2Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA USA
| | - Bruce Bauer
- 3Division of Plastic and Reconstructive Surgery, North Shore University Health System, Northbrook, IL USA
| | - Miguel Reyes-Múgica
- Department of Pathology, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15224 USA
| |
Collapse
|
7
|
Mauger F, How-Kit A, Tost J. COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications. Mol Diagn Ther 2018; 21:269-283. [PMID: 28101802 DOI: 10.1007/s40291-016-0254-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Somatic mutations bear great promise for use as biomarkers for personalized medicine, but are often present only in low abundance in biological material and are therefore difficult to detect. Many assays for mutation analysis in cancer-related genes (hotspots) have been developed to improve diagnosis, prognosis, prediction of drug resistance, and monitoring of the response to treatment. Two major approaches have been developed: mutation-specific amplification methods and methods that enrich and detect mutations without prior knowledge on the exact location and identity of the mutation. CO-amplification at Lower Denaturation temperature Polymerase Chain Reaction (COLD-PCR) methods such as full-, fast-, ice- (improved and complete enrichment), enhanced-ice, and temperature-tolerant COLD-PCR make use of a critical temperature in the polymerase chain reaction to selectively denature wild-type-mutant heteroduplexes, allowing the enrichment of rare mutations. Mutations can subsequently be identified using a variety of laboratory technologies such as high-resolution melting, digital polymerase chain reaction, pyrosequencing, Sanger sequencing, or next-generation sequencing. COLD-PCR methods are sensitive, specific, and accurate if appropriately optimized and have a short time to results. A large variety of clinical samples (tumor DNA, circulating cell-free DNA, circulating cell-free fetal DNA, and circulating tumor cells) have been studied using COLD-PCR in many different applications including the detection of genetic changes in cancer and infectious diseases, non-invasive prenatal diagnosis, detection of microorganisms, or DNA methylation analysis. In this review, we describe in detail the different COLD-PCR approaches, highlighting their specificities, advantages, and inconveniences and demonstrating their use in different fields of biological and biomedical research.
Collapse
Affiliation(s)
- Florence Mauger
- Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA-Institut de Génomique, Batiment G2, 2 rue Gaston Crémieux, 91000, Evry, France
| | - Alexandre How-Kit
- Laboratory for Genomics, Fondation Jean Dausset-CEPH, 75010, Paris, France
| | - Jörg Tost
- Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA-Institut de Génomique, Batiment G2, 2 rue Gaston Crémieux, 91000, Evry, France.
| |
Collapse
|
8
|
Guégan S, Kadlub N, Picard A, Rouillé T, Charbel C, Coulomb-L'Hermine A, How-Kit A, Fraitag S, Aractingi S, Fontaine RH. Varying proliferative and clonogenic potential inNRAS-mutated congenital melanocytic nevi according to size. Exp Dermatol 2016; 25:789-96. [DOI: 10.1111/exd.13073] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Sarah Guégan
- Institut National de la Santé et de la Recherche Médicale (INSERM), U938; Saint-Antoine Research Center; Paris France
- Université Pierre et Marie Curie-Paris VI; Paris France
- Department of Dermatology; Assistance Publique-Hôpitaux de Paris, Hôpital Tenon; Paris France
| | - Natacha Kadlub
- Université René Descartes-Paris V; Paris France
- Department of Maxillofacial and Plastic Surgery; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants-Malades; Paris France
| | - Arnaud Picard
- Université René Descartes-Paris V; Paris France
- Department of Maxillofacial and Plastic Surgery; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants-Malades; Paris France
| | - Thomas Rouillé
- Institut National de la Santé et de la Recherche Médicale (INSERM), U938; Saint-Antoine Research Center; Paris France
- Université Pierre et Marie Curie-Paris VI; Paris France
| | - Christelle Charbel
- Institut National de la Santé et de la Recherche Médicale (INSERM), U938; Saint-Antoine Research Center; Paris France
- Université Pierre et Marie Curie-Paris VI; Paris France
| | - Aurore Coulomb-L'Hermine
- Université Pierre et Marie Curie-Paris VI; Paris France
- Department of Pathology; Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau; Paris France
| | - Alexandre How-Kit
- Laboratory for Functional Genomics; Fondation Jean Dausset - CEPH; Paris France
| | - Sylvie Fraitag
- Department of Pathology; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants-Malades; Paris France
| | - Selim Aractingi
- Institut National de la Santé et de la Recherche Médicale (INSERM), U938; Saint-Antoine Research Center; Paris France
- Université René Descartes-Paris V; Paris France
- Department of Dermatology; Assistance Publique-Hôpitaux de Paris, Hôpital Cochin; Paris France
| | - Romain H. Fontaine
- Institut National de la Santé et de la Recherche Médicale (INSERM), U938; Saint-Antoine Research Center; Paris France
- Université Pierre et Marie Curie-Paris VI; Paris France
| |
Collapse
|
9
|
Maruani A. [What's new in pediatric dermatology?]. Ann Dermatol Venereol 2016; 142 Suppl 3:S26-35. [PMID: 26792412 DOI: 10.1016/s0151-9638(16)30004-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The years 2014-2015 have been rich in paediatric dermatology news in varied areas. Randomized controlled trials including children have been performed, especially in the fields of vascular anomalies, infectiology and immuno-allergology; new classifications and guidelines have been established; scientific research has made new discoveries, including the molecular basis of pediatric nevi and melanoma; epidemiologic works on risk factors have highlighted the need for dermatologists to be aware of prevention (sun prevention but also obesity); and finally, the many publications have taken into account psychological issues in children, such as quality of life, pain, observance or acceptance.
Collapse
Affiliation(s)
- A Maruani
- Service de dermatologie, unité de dermatologie pédiatrique, hôpital Trousseau, avenue de la République, 37044 Tours Cedex 9 ; université François-Rabelais de Tours, INSERM U930, 37000 Tours, France.
| |
Collapse
|
10
|
Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res 2016; 28:661-72. [PMID: 26300491 DOI: 10.1111/pcmr.12412] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 08/19/2015] [Indexed: 01/05/2023]
Abstract
Melanocytic nevi are a benign clonal proliferation of cells expressing the melanocytic phenotype, with heterogeneous clinical and molecular characteristics. In this review, we discuss the genetics of nevi by salient nevi subtypes: congenital melanocytic nevi, acquired melanocytic nevi, blue nevi, and Spitz nevi. While the molecular etiology of nevi has been less thoroughly studied than melanoma, it is clear that nevi and melanoma share common driver mutations. Acquired melanocytic nevi harbor oncogenic mutations in BRAF, which is the predominant oncogene associated with melanoma. Congenital melanocytic nevi and blue nevi frequently harbor NRAS mutations and GNAQ mutations, respectively, while Spitz and atypical Spitz tumors often exhibit HRAS and kinase rearrangements. These initial 'driver' mutations are thought to trigger the establishment of benign nevi. After this initial phase of the cell proliferation, a senescence program is executed, causing termination of nevi growth. Only upon the emergence of additional tumorigenic alterations, which may provide an escape from oncogene-induced senescence, can malignant progression occur. Here, we review the current literature on the pathobiology and genetics of nevi in the hope that additional studies of nevi promise to inform our understanding of the transition from benign neoplasm to malignancy.
Collapse
Affiliation(s)
- Mi Ryung Roh
- Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Department of Dermatology, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
| | - Philip Eliades
- Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Tufts University School of Medicine, Boston, MA, USA
| | - Sameer Gupta
- Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Hensin Tsao
- Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
11
|
|
12
|
Basu D, Salgado CM, Bauer BS, Johnson D, Rundell V, Nikiforova M, Khakoo Y, Gunwaldt LJ, Panigrahy A, Reyes-Múgica M. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway. Neuro Oncol 2015; 18:528-37. [PMID: 26354928 DOI: 10.1093/neuonc/nov184] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 08/04/2015] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Neurocutaneous melanocytosis (NCM) is characterized by clonal nevomelanocytic proliferations in the CNS and skin. Given the scarcity of effective therapeutic targets, testing new drugs requires a reliable and reproducible in vitro cellular model of the disease. METHODS We generated nevomelanocytic spheroids in vitro from lesions of the spinal cord, brain, and skin from 4 NCM patients. Nevomelanocytic cells were grown as monolayers or spheroids and their growth characteristics were evaluated. Cultured cell identity was confirmed by demonstration of the same NRAS mutation found in the original lesions and by immunophenotyping. Nevomelanocytic spheroids were treated with inhibitors of specific mediators of the NRAS signaling pathway (vemurafenib, MEK162, GDC0941, and GSK2126458). Drug sensitivity and cell viability were assessed. RESULTS Cultured cells were growth-factor dependent, grew as spheroids on Geltrex matrix, and maintained their clonogenicity in vitro over passages. Skin-derived cells formed more colonies than CNS-derived cells. Inhibitors of specific mediators of the NRAS signaling pathway reduced viability of NRAS mutated cells. The highest effect was obtained with GSK2126458, showing a viability reduction below 50%. CONCLUSIONS NRAS mutated cells derived from clinical NCM samples are capable of continuous growth as spheroid colonies in vitro and retain their genetic identity. Drugs targeting the NRAS signaling pathway reduce in vitro viability of NCM cells. NCM lesional spheroids represent a new and reliable experimental model of NCM for use in drug testing and mechanistic studies.
Collapse
Affiliation(s)
- Dipanjan Basu
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Cláudia M Salgado
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Bruce S Bauer
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Donald Johnson
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Veronica Rundell
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Marina Nikiforova
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Yasmin Khakoo
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Lorelei J Gunwaldt
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Ashok Panigrahy
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Miguel Reyes-Múgica
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| |
Collapse
|
13
|
Cells to surgery quiz: March 2015. J Invest Dermatol 2015; 135:1-2. [PMID: 25666676 DOI: 10.1038/jid.2014.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|